Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops, solution - excipient ingredients: mannitol; sodium citrate dihydrate; benzalkonium chloride; hyetellose; water for injections; sodium hydroxide - trusopt eye drops are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open- angle glaucoma.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - dorzolamide hydrochloride 2.226%{relative} equivalent to dorzolamide base 2% - eye drops, solution - 2 % - active: dorzolamide hydrochloride 2.226%{relative} equivalent to dorzolamide base 2% excipient: benzalkonium chloride hyetellose mannitol sodium citrate dihydrate sodium hydroxide water for injection - trusopt ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with: · ocular hypertension · open-angle glaucoma · pseudoexfoliative glaucoma and other secondary open-angle glaucomas · in the short-term treatment of paediatric glaucomas as adjunctive therapy to beta-blockers and for monotherapy when other treatments have proved ineffective or are unsuitable.

Израел - Енглески - Ministry of Health

rafa laboratories ltd - dorzolamide as hydrochloride - ophthalmic solution - dorzolamide as hydrochloride 20 mg/ml - dorzolamide - dorzolamide - for the treatment of eleveated intraocular pressure in patients with ocular hypertension, open-angle glaucoma and in some patients secondary glaucoma.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

merck sharp & dohme llc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - trusopt® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. trusopt is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)] . risk summary there are no adequate and well-controlled studies in pregnant women with trusopt. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general populati

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

santen uk ltd - dorzolamide hydrochloride - eye drops - 20mg/1ml

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - dorzolamide hydrochloride -

Малта - Енглески - Medicines Authority

merck sharp & dohme limited hertford road, hoddesdon, hertfordshire en11 9bu, united kingdom - dorzolamide - eye drops, solution - dorzolamide 20 mg/ml - ophthalmologicals

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

santen oy - dorzolamide hydrochloride - eye drops, solution - 20 milligram(s)/millilitre - dorzolamide - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors, dorzolamide - it is indicated: as adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated, in the treatment of elevated intra-ocular pressure in: ocular hypertension, open-angle glaucoma, pseudoexfoliative glaucoma.

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

santen oy - dorzolamide - eye drops, solution in single-dose container - 20 milligram(s)/millilitre - carbonic anhydrase inhibitors; dorzolamide - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors, dorzolamide - it l is indicated: as adjunctive therapy to beta-blockers; as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated; in the treatment of elevated intra-ocular pressure in: ocular hypertension; open-angle glaucoma; pseudoexfoliative glaucoma.

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

santen uk ltd - dorzolamide hydrochloride - eye drops - 20mg/1ml